Synthesis of AWB158, AWZ1066S (and its HCl salt), and Photoreactive probe 1 & 2
All reactions were carried out in oven-dried glassware sealed with rubber septa under nitrogen. Anhydrous solvents and reagents were purchased from reliable commercial sources and were used without any purification unless otherwise indicated. TLC was performed on 0.25 mm thickness Merck silica gel 60 with fluorescent indicator at 254 nm and visualised under UV light. Flash column chromatography was performed using normal phase silica gel purchased from Sigma-Aldrich. NMR spectra were recorded on Brucker AMX400 spectrometer. Chemical shifts (δ) were expressed in ppm relative to tetramethylsilane (TMS) used as an internal standard. Mass spectra were recorded on Micromass LCT Mass Spectrometer using electrospray ionisation (ESI). Purity was determined by HPLC analysis using an Agilent 1200 system with the following conditions: ZORBAX Eclipse Plus C18 (4.6 mm x 100 mm, 3.5 µm) at 25 ⁰C with 1.0 mL/min flow rate; solvents -A) water +/-0.05% trifluoroacetic acid (TFA) and B) acetonitrile +/-0.05% TFA; method: Run time: 15 min, gradient: 2% B hold to 1 min, 2-98% B in 11 min, then hold at 98% B to 15 min. The Synthesis of N 2 -isopropyl-N 4 -(2-(trifluoromethyl)benzyl)thieno [3,2-d] pyrimidine-2,4-diamine (AWB124) was described previously.(1) N 2 -isopropyl-N 4 -(2-(trifluoromethyl)benzyl)quinazoline-2,4-diamine (AWB158). To a suspension of 2,4-dichloroquinazoline (0.40 g, 2 mmol) in THF (10 mL) was added triethylamine (0.56 mL) followed by 2-(trifluoromethyl)benzylamine (0.42 g). The mixture was heated to 80 o C for 3 h (followed by TLC). Subsequently, the reaction was cooled to room temperature and water (30 mL) was added. The mixture was cooled in an ice bath, and the resulting precipitates were collected. The crude was purified by column chromatography using 5-10% methanol in dichloromethane to give 2-chloro-N-(2-(trifluoromethyl)benzyl)quinazolin-4-amine as a yellow solid (0.63 g, 93 %). To a microwave tube was charged 2-chloro-N-(2-(trifluoromethyl)benzyl)quinazolin-4-amine (0.68g, 2 mmol) and isopropylamine (1.72 mL) in 1,4-dioxane (5 mL). The mixture was irradiated at 200 o C by microwave radiation for 1 h (followed by TLC). The reaction was cooled to room temperature and the solvent was removed. The crude was purified by column chromatography using 5-10% methanol in dichloromethane to give N 2 -isopropyl-N 4 -(2-(trifluoromethyl)benzyl)quinazoline-2,4-diamine as a white solid (0.36 g, 50 %). [2,3-d] pyrimidin-4-amine (4.84 g, 12.0 mmol) in acetone (50 mL) was added 4N HCl in 1,4-dioxane (4.5 mL). The resulting mixture was allowed to stir at room temperature overnight. The solvent was removed in vacuo to give the HCl salt as a yellow solid (quantitative).
(S)-2-(3-methylmorpholino)-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)pyrido[2,3d]pyrimidin-4-amine (AWZ1066S and HCl salt

2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2yl)piperidin-4-yl)ethyl (2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethyl)carbamate (Photoreactive probe 1).
To a microwave tube was charged 2-chloro-N-(2-(trifluoromethyl)benzyl)quinazolin-4-amine (0.68 g, 2 mmol), 1,3-dioxane (8 mL), 4piperidineethanol (0.31 g) and triethylamine (0.56 mL). The mixture was irradiated by microwave at 200 o C for 1 h (followed by TLC). The reaction was cooled to room temperature and the solvent was removed. The crude was purified by column chromatography using 2-10% methanol in dichloromethane to give 2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2-yl)piperidin-4-yl)ethan-1-ol (Int_A) as a yellow solid (0.64 g, 74%). To a light yellow solution of Int_A (0.24 g, 0.56 mmol) in acetonitrile (15 mL) and chloroform (5 mL) was added N,N-disuccinimidyl carbonate (0.22 g) followed by triethylamine (0.12 mL). The yellow solution was allowed to stir at room temperature for 2 h and 50 o C for 2.5 h, then 25 o C overnight (followed by TLC). Saturated NaHCO 3 (aq.) was added to quench the reaction. The reaction was extracted by dichloromethane (X3), the combined organic layers were washed with brine, dried over MgSO 4 , filtered and concentrated. The crude was purified by column chromatography using 2-10% methanol in dichloromethane to give 2,5-dioxopyrrolidin-1-yl ( 
. To a yellow solution of Int_B (101 mg, 0.18 mmol) in chloroform (8 mL) was added 2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethan-1amine (23.5 mg) followed by triethylamine (40 µL). The resulting solution was allowed to stir at room temperature overnight under dark environment (followed by TLC). The solvent was removed and the crude was purified by column chromatography using 5% methanol in ethyl acetate to give 2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2-yl)piperidin-4-yl)ethyl (2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethyl)carbamate as a pale yellow powder (26 mg, 25%).
2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2yl)piperidin-4-yl)ethyl (1-oxo-1-((4-(3-(trifluoromethyl)-3H-diazirin-3yl)benzyl)amino)pent-4-yn-2-yl)carbamate (Photoreactive probe 2).
To a yellow solution of Int_B (74 mg, 0.13 mmol) in chloroform (8 mL) was added 2-amino-N-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzyl)pent-4-ynamide (40 mg) followed by triethylamine (27 µL). The resulting solution was allowed to stir at room temperature overnight under dark environment (followed by TLC). The solvent was removed and the crude was purified by column chromatography using 5% methanol in ethyl acetate to give 2-
Preliminary target pulldown using photoreactive probes with Wolbachia infected cells
Sample preparation and pull-down for proteomics; cells from multiple confluent flasks were combined, aliquoted and incubated with probes at a final concentration of 5 µM for 2 h at 26 °C in complete medium. DMSO was used for "no probe" controls. All conditions were conducted in triplicate. Cells were washed twice with phosphate buffered saline (PBS), resuspended in 0.5 ml PBS and added to a six-well plate. Each sample was subjected to photo-crosslinking with UV (365 nm) for 5 min, then immediately lysed by adding 50 µl PBS containing 10% Triton X-100, 1% sodium dodecyl sulphate (SDS) and 10x EDTA-free protease inhibitor mix (Roche) (final concentration of 1% Triton X-100, 0.1% SDS and 1x protease inhibitor mix). Protein concentrations were determined using the DC protein assay (Biorad) and equivalent quantities of total protein (700 µg) were used for all samples in the subsequent copper-catalysed cycloaddition reaction to conjugate the probes to azide-TAMRA-biotin (AzTB). (2) The following final concentrations of reagents were used: 0.1 mM AzTB, 1 mM CuSO 4 , 2 mM tris(2-carboxyethyl)phosphine (TCEP) and 0.2 mM tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA). Following 1 h incubation with shaking at room temperature, the reaction was stopped by adding ethylene diaminetetraacetic acid (final concentration 5 mM). Proteins were precipitated using methanol and chloroform(2) and dissolved in 100 µl 2% SDS then diluted to 0.4% with PBS. Neutravidin agarose beads (Thermo Fisher Scientific) were washed twice in 0.4% SDS, then incubated with protein samples at room temperature with gentle shaking for 2 h. Beads were recovered by centrifugation at 6000 g for 4 min then subjected to a total of nine 1ml washes (2 x 0.4% SDS, 1 x water, 6 x 50 mM NH 4 HCO 3 ). Bead-bound proteins were subjected to overnight incubation at 37 °C with 0.02 µg/ml sequencing grade trypsin (Promega), 5mM TCEP, and 15mM chloroacetamide in 100 µl of 50 mM NH 4 HCO 3 . Supernatant was harvested by centrifugation and the beads were washed with 48 µl of 1.5% TFA and pelleted. The two supernatants (i.e. before and after TFA treatment) were combined and peptides were purified by stage-tip.(2) Purified peptides were eluted in 60 µl of 60% acetonitrile in water and dried.
LC-MS/MS analysis of proteomics samples and data processing;
peptides were reconstituted in 10 μL of 0.5% TFA, 2% acetonitrile in water, of which 1 μL was analysed on an Easy nLC-1000 system coupled to a QExactive mass spectrometer via an easy-spray source (all Thermo Fisher Scientific).(2) The data were processed with MaxQuant version 1.6.0.1(3) and the peptides were identified from the MS/MS spectra searched against the W. pipientis (proteome ID UP000218863, version 27.02.2018) and A. albopictus (UP000069940, version 13.03.2018) databases from Swissprot+TrEMBL. Peptides and proteins were identified at the fixed false discovery rate (FDR) of 0.01, with "Unique and razor peptides" (razor peptides are uniquely assigned to protein groups and not to individual proteins) used for protein grouping and LFQ quantification. All parameters were used as pre-set in the software. The content of MaxQuant-generated protein group.txt file was analysed using Perseus version 1.6.0.2(4) and Microsoft Office Excel 2016. Peptides categorised by MaxQuant as 'potential contaminants', 'only identified by site' or 'reverse' were filtered off, and the processed LFQ intensities transformed in Log2(LFQ). Two unique/razor peptides were required for protein identification. LFQ values were required to be present in at least 2 out of 3 samples derived from chemical probe-treated cells. Missing values in samples derived from vehicle (DMSO)-treated cells were replaced from a normal distribution with width 0.3 and downshift 1.8. Two right sided t-tests (permutation based FDR=0.001 and S0=3) were performed to assess proteins significantly enriched in samples derived from chemical probe-treated samples compared with those derived from DMSO-treated controls (Supplementary information Figure 2 ). Figure S1 . a) SAR of azaquinazoline series; b) representatives of different sub-series and their key in vitro data with key weaknesses highlighted in red; c) current scale-up synthetic route to AWZ1066S.
Supplementary
Supplementary Figure S2: Putative protein targets of photoreactive probes 1 (A) and 2 (B) assigned based on statistical testing (right-sided t-test, permutation based FDR=0.001, S0=3) of LFQ intensities measured in samples derived from probe-treated cells and control, DMSO-treated cells. T-test differences between mean Log2 LFQ intensities of probe and DMSO samples are plotted along the x-axis and -Log10 t-test p-values along the y-axis.
Each dot on the graph represents protein (occasionally a small group of proteins). Grey points did not meet the t-test criteria of significance, whereas blue (W. pipientis) and red (A. albopictus) points did.
In vitro Hepatocytes Clint (µL/min/million cells ) Species
AWZ1066S AWZ1066R Supplementary Table S4 : Mouse PK profiles of AWZ1066S and its mesylate salt in BALB/c mice (studies were conducted by Eisai (n = 3)). Note: * Studies were carried out with BALB/c SCID mice by Wuxi AppTec (n = 3); # dosed as salt form and the salt dosages are described as they are in the equivalent free base form. All in vivo pharmacokinetic studies conformed to AAALAC International and NIH guidelines as reported in the Guide for the Care and Use of Laboratory Animals, National Research Council (2011); People's Republic of China, Ministry of Science & Technology, "Regulations for the Administration of Affairs Concerning Experimental Animals," 1988. Supplementary Table S6 : Predicted human pharmacokinetic parameters. The prediction of the pharmacokinetic properties required the estimation of the following parameters: Clearance was predicted from human hepatocyte data, using standard scaling methodologies and the well-stirred liver model. Vss was predicted from in vivo PK data across species, accounting for any species dependent differences in measured plasma protein binding. Bioavailability was estimated from the predicted hepatic extraction and the absorption observed in animal PK profiles. Supplementary Table S9 : AWZ1066S tested for micronucleus in vivo in the mouse. AWZ1066S was dosed orally twice at 1000 mg/kg, with a 24 hour interval in between, to male CD-1 mice (n = 3). The negative control group (Control) received an equivalent volume of vehicle (0.2 mol/L hydrochloric acid, 20 ml/kg) and the positive control group (CP) received cyclophosphamide orally at 40 mg/kg twice in the same dosing regimen of AWZ1066S. All animals were euthanized 48 hours after the first administration. Bone marrow cells were collected from the femurs, fixed in neutral buffered 10% formalin, and stained with acridine orange for observation. E = erythrocytes, MNPCE = micronucleated polychromatic erythrocytes, PCE = polychromatic erythrocytes, n.s. = not significant, *** Chisquare test (p < 0.001). Study was conducted by Eisai and conformed to AAALAC International and NIH guidelines as reported in the Guide for the Care and Use of Laboratory Animals, National Research Council (2011). Supplementary Table S10 : AWZ1066S tested in cardiovascular study with anesthetised and conscious rats (n = 3). AWZ1066S was dosed intravenously at the doses described in the table and the drug concentrations was measured from the plasma samples took after 5 minute of dosing. HR: heart rate, BP: blood pressure, PR: PR interval in ECG waveform, QRS: QRS duration in ECG waveform, QA: QA interval. All parameters were described as mean % changes in comparison to control group. Study was conducted by Eisai and conformed to AAALAC International and NIH guidelines as reported in the Guide for the Care and Use of Laboratory Animals, National Research Council (2011).
Supplementary
Anesthetized rats
Conscious rats
